Lexaria Bioscience Corp. commented on an independent January 10 study, available here, that discovered that Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants. In the peer-reviewed study, the researchers concluded that "Cannabinoid acids from hemp (Cannabis sativa) were found to be allosteric as well as orthosteric ligands with micromolar affinity for the spike protein.

In follow-up virus neutralization assays, cannabigerolic acid and cannabidiolic acid prevented infection of human epithelial cells by a pseudovirus expressing the SARS-CoV-2 spike protein and prevented entry of live SARS-CoV-2 alpha variant B.1.1.7 and the beta variant B.1.351. Lexaria is actively engaged in research with DehydraTECH-powered cannabinoid formulations across a range of potential therapeutic applications, including an advanced oral DehydraTECH- CBD formulation that it is preparing for registered clinical trials as a prospective new pharmaceutical product. Moreover, the patented DehydraTECH process does not involve processing temperatures remotely as high as those encountered in smoking or vaping processes, and in previous studies has been found to leave the cannabinoid molecules undamaged.

In other work previously conducted by Lexaria and announced on June 3, 2021, discovered that Lexaria's DehydraTECH-enabled remdesivir and ebastine effectively inhibit the COVID-19 SARS-CoV-2 Virus. Remdesivir is a well-known nucleotide reverse transcriptase inhibitor, available under the trade name Veklury® from Gilead Sciences Inc., that interferes with the SARS- CoV-2 viral replication life cycle and has received emergency use authorization in many regions of the world for treatment of COVID-19. Ebastine is an antihistamine drug that has potent effects in inhibiting the SARS-CoV-2 main protease (Mpro, also called the 3CL protease) blocking viral entry into human cells, together with effects to reduce COVID-19 inflammatory reactions.

Mpro inhibitors are gaining attention in the fight against COVID-19, as announced by Pfizer with their novel compound PF-07304814. The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain COVID-19 (or the SARS-CoV-2) virus.